OSC is a rare cancer in the UK

Article

Ocular sebaceous carcinoma (OSC) has been confirmed as a rare cancer in the UK, claims a recent study.

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Related Content
A petri dish with a fungal growth in solution sits beneath a microscope. Image credit: ©angellodeco – stock.adobe.com

Plant pathogen Macrophomina phaseolina may be emerging cause of ocular infection in humans

Lynda Charters
January 17th 2025
Article

A case report highlights the pathogen’s potential to cause severe, devastating ocular infections, despite aggressive treatment

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
An illustration of a brain, and a superimposed image of molecular structure and genetic helixes, all in green/blue. Image credit: ©kittyfly – stock.adobe.com

RhyGaze announces $86 million in Series A financing for optogenetic vision restoration therapy candidate

Grace Koennecke
January 16th 2025
Article

The company, which has European headquarters in Basel, Switzerland, plans to use the funds for a non-interventional, observational study and a first-in-human clinical trial

A sign outside the US Food and Drug Administration headquarters. Image credit: ©Tada Images – stock.adobe.com

US FDA approves Zeiss MEL 90 excimer laser for myopia, hyperopia and mixed astigmatism

Jordana Joy
January 14th 2025
Article

The laser integrates into the Corneal Refractive Workflow alongside the Visumax 800 and SMILE pro software

A black-and-white photo of a handshake with the logos for Formycon, Klinge Biopharma and Teva over them.

Teva partners with Klinge Biopharma for commercialisation of Formycon’s FYB203 (biosimilar aflibercept)

Hattie Hayes
January 13th 2025
Article

The commercialisation agreement for the biosimilar to aflibercept (Eylea) covers Israel and major parts of Europe, excluding Italy

Bausch + Lomb launches its enVista Aspire monofocal and toric intraocular lenses in the European Union

Bausch + Lomb launches its enVista Aspire monofocal and toric intraocular lenses in the European Union

Martin David Harp
January 13th 2025
Article

The launch follows a CE Mark received in late 2024

© 2025 MJH Life Sciences

All rights reserved.